Alternative therapies for chronic Hepatitis B patients with partial virological response to standard entecavir monotherapy

Journal of Clinical Gastroenterology

Volumn 50, Issue 4, 2016, Pages 338-344

  Chaung, Kevin T ^a   O'Brien, Connor ^b   Ha, Nghiem B ^c,d   Nguyen, Nghia H ^c,e   Trinh, Huy N ^f,g   Nguyen, Mindie H ^c  

^a ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f San Jose Gastroenterology   (United States)

^g Pacific Health Foundation   (United States)

Author keywords

chronic hepatitis B; complete viral suppression; entecavir; partial responders; partial virologic response; recurrent viremia; tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; GUANINE; VIRUS DNA;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; ASIAN; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; ANALOGS AND DERIVATIVES; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG SUBSTITUTION; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; UNITED STATES; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG SUBSTITUTION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84949579946     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000455     Document Type: Article

References (31)

1. World Health Organization. Hepatitis B (No. 204) [Fact sheet]. 2014. Available at: http://www.who.int/mediacentre/factsheets/.fs204/en/. Accessed April. 2, 2015.
2. Keeffe EB, Dieterich DT, Han SH, et al A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008; 6: 1315-1341.
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61: 1942-1956.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45: 507-539.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-662.
6. McMahon BJ. Natural history of chronic hepatitis B-clinical implications. Medscape J Med. 2008; 10: 91.
7. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999; 89: 14-18.
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48: 335-352.
10. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007; 5: 921-931.
11. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130: 678-686.
12. Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology. 2007; 132: 2340-2345.
13. Keeffe EB, Dieterich DT, Pawlotsky JM, et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008; 6: 268-274.
14. Tenney DJ, Pokornowski KA, Rose REE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. Gastroenterology. 2009; 136: A-865.
15. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-Analyses. Gastroenterology. 2010; 139: 1218-1229.
16. Kim JH, Lee SJ, Joo MK, et al. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation. Dig Dis Sci. 2009; 54: 1572-1577.
17. Nguyen MH, Keeffe EB. Are hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and HBeAg-negative chronic hepatitis B distinct diseases?. Clin Infect Dis. 2008; 47: 1312-1314.
18. Yang YJ, Shim JH, Kim KM, et al. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014; 59: 1303-1310.
19. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011; 54: 443-451.
20. Tenney DJ, Rose RE, Baldick CJ, et al. Long-Term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology. 2009; 49: 1503-1514.
21. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006; 44: 1656-1665.
22. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007; 133: 1437-1444.
23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50: 227-242.
24. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2: 263-283.
25. Paul N, Han SH. Combination therapy for chronic hepatitis B: current indications. Curr Hepat Rep. 2011; 10: 98-105.
26. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004; 48: 3498-3507.
27. Chen CH, Hu TH, Hung CH, et al. Antiviral effect of entecavir in nucleos(t)ide analogue-naive and nucleos(t)ide analogueexperienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat. 2014; 21: e55-e64.
28. Lu L, Yip B, Trinh H, et al. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. J Viral Hepat. 2015; 22: 675-681.
29. Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 2012; 19: 213-219.
30. Yip B, Chaung K, Wong CR, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci. 2012; 57: 3011-3016.
31. Ha NB, Ha NB, Chaung KT, et al. Similar response to entecavir 0.5 and 1.0 mg in treatment-naive chronic hepatitis B patients: a case-control study. Dig Dis Sci. 2014; 59: 168-173.